Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded by Wall Street Zen to Sell Rating

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research note issued on Saturday.

A number of other analysts also recently weighed in on RVPH. D. Boral Capital downgraded shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Chardan Capital restated a “buy” rating and set a $40.00 price objective on shares of Reviva Pharmaceuticals in a research report on Monday, January 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $66.67.

Reviva Pharmaceuticals Stock Down 6.8%

RVPH opened at $2.47 on Friday. The stock has a market capitalization of $14.42 million, a price-to-earnings ratio of -0.27 and a beta of 0.10. Reviva Pharmaceuticals has a twelve month low of $2.37 and a twelve month high of $23.40. The company has a 50-day simple moving average of $5.40 and a 200 day simple moving average of $8.47.

Institutional Trading of Reviva Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Armistice Capital LLC acquired a new position in shares of Reviva Pharmaceuticals during the second quarter worth $1,026,000. Millennium Management LLC boosted its holdings in shares of Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after acquiring an additional 223,178 shares in the last quarter. Geode Capital Management LLC grew its position in Reviva Pharmaceuticals by 87.6% during the 4th quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock worth $293,000 after acquiring an additional 489,711 shares during the last quarter. 683 Capital Management LLC bought a new stake in Reviva Pharmaceuticals during the 2nd quarter worth $381,000. Finally, Persistent Asset Partners Ltd increased its holdings in Reviva Pharmaceuticals by 300.0% in the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after purchasing an additional 480,864 shares in the last quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.